Workshop highlights include:
- Sharing feedback from a recent meeting with the FDA on ADC control strategies including regulatory starting materials, impurity control, release testing, and comparability
- Assessing drug-linker attributes in the context of the ADC drug product and its utility in establishing specifications, impurity control strategies, and comparability approaches
- Discussing industry experiences with post-approval changes to drug-linker processes and a framework for managing such changes